STUDY OBJECTIVE: To determine the hemodynamic and cognitive effects of lofexidine and methadone coadministration. DESIGN: Prospective, double-blind study. SETTING: Outpatient drug treatment research clinic. SUBJECTS:Fourteen participants (aged 18-45 yrs) with physical dependence on opioids. INTERVENTION: Subjects were stabilized on methadone maintenance therapy, starting with 30 mg/day and increasing by 10-mg/day increments, based on each subject's tolerability to achieve a target dose of 80 mg/day. After 3 weeks of methadone stabilization, lofexidine 0.4 mg/day or matching placebo were coadministered with methadone, in doses escalating by 0.2-mg/week increments, to achieve a target dose of 1.6 mg/day over the next 8 weeks. MEASUREMENTS AND MAIN RESULTS:Acute orthostatic vital signs and neuropsychological effects of lofexidine and methadone coadministration were monitored for 5 hours after the dose on the first day of each new lofexidine dose. Orthostatic vital signs and adverse events were assessed daily thereafter to determine the effects of repeated doses. Lofexidine significantly decreased sitting systolic and diastolic blood pressure (p=0.045 and p=0.033, respectively) compared with placebo (i.e., methadone alone). With lofexidine 0.4 mg/day, mean decreases in systolic and diastolic blood pressure were 27 +/- 17 and 15 +/- 16 mm Hg, respectively. No significant association was noted between changes in orthostatic vital signs and lofexidine dose. Decreased cognitive efficiency was associated with lofexidine administration, and higher lofexidine doses adversely affected performance on a mathematical task compared with placebo (p=0.0035). The rate of adverse events was no higher with lofexidine than with placebo; the majority (54.3%) were common adverse effects of lofexidine. CONCLUSION: Significant changes in hemodynamic and cognitive efficiency were observed with coadministration of lofexidine and methadone compared with methadone alone. When patients receiving methadone are prescribed lofexidine, they should be closely monitored for cardiovascular and cognitive changes.
RCT Entities:
STUDY OBJECTIVE: To determine the hemodynamic and cognitive effects of lofexidine and methadone coadministration. DESIGN: Prospective, double-blind study. SETTING:Outpatient drug treatment research clinic. SUBJECTS: Fourteen participants (aged 18-45 yrs) with physical dependence on opioids. INTERVENTION: Subjects were stabilized on methadone maintenance therapy, starting with 30 mg/day and increasing by 10-mg/day increments, based on each subject's tolerability to achieve a target dose of 80 mg/day. After 3 weeks of methadone stabilization, lofexidine 0.4 mg/day or matching placebo were coadministered with methadone, in doses escalating by 0.2-mg/week increments, to achieve a target dose of 1.6 mg/day over the next 8 weeks. MEASUREMENTS AND MAIN RESULTS: Acute orthostatic vital signs and neuropsychological effects of lofexidine and methadone coadministration were monitored for 5 hours after the dose on the first day of each new lofexidine dose. Orthostatic vital signs and adverse events were assessed daily thereafter to determine the effects of repeated doses. Lofexidine significantly decreased sitting systolic and diastolic blood pressure (p=0.045 and p=0.033, respectively) compared with placebo (i.e., methadone alone). With lofexidine 0.4 mg/day, mean decreases in systolic and diastolic blood pressure were 27 +/- 17 and 15 +/- 16 mm Hg, respectively. No significant association was noted between changes in orthostatic vital signs and lofexidine dose. Decreased cognitive efficiency was associated with lofexidine administration, and higher lofexidine doses adversely affected performance on a mathematical task compared with placebo (p=0.0035). The rate of adverse events was no higher with lofexidine than with placebo; the majority (54.3%) were common adverse effects of lofexidine. CONCLUSION: Significant changes in hemodynamic and cognitive efficiency were observed with coadministration of lofexidine and methadone compared with methadone alone. When patients receiving methadone are prescribed lofexidine, they should be closely monitored for cardiovascular and cognitive changes.
Authors: Ziva D Cooper; Kirk W Johnson; Martina Pavlicova; Andrew Glass; Suzanne K Vosburg; Maria A Sullivan; Jeanne M Manubay; Diana M Martinez; Jermaine D Jones; Phillip A Saccone; Sandra D Comer Journal: Addict Biol Date: 2015-05-14 Impact factor: 4.280
Authors: Michelle L Jobes; Udi E Ghitza; David H Epstein; Karran A Phillips; Stephen J Heishman; Kenzie L Preston Journal: Psychopharmacology (Berl) Date: 2011-03-12 Impact factor: 4.530
Authors: John Schmittner; Jennifer R Schroeder; David H Epstein; Mori J Krantz; Nicole C Eid; Kenzie L Preston Journal: Pharmacotherapy Date: 2009-05 Impact factor: 4.705
Authors: Ivan Urits; Anjana Patel; Robbie Zusman; Celina Guadalupe Virgen; Mohammad Mousa; Amnon A Berger; Hisham Kassem; Jai Won Jung; Jamal Hasoon; Alan D Kaye; Omar Viswanath Journal: Psychopharmacol Bull Date: 2020-07-23